# Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
Canonical URL: https://biopharmsignal.com/news/LYRA/lyra-therapeutics-to-present-52-week-extension-stage-results-for-enlighten-1-phase-3-study-for-lyr-210-for-the-treatment-of-chronic-rhinosinusitis-at-cosm-2025
Ticker: LYRA
Company: Lyra Therapeutics
Source: Lyra Therapeutics
Published: 2025-05-07 11:00 EST
Original Source URL: https://investors.lyratherapeutics.com
## Summary

Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS  In the CRS patient subgroup with nasal polyps, analysis showed improvements in both symptoms and polyp size in Sham group patients

## Article Body
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS  In the CRS patient subgroup with nasal polyps, analysis showed improvements in both symptoms and polyp size in Sham group patients
## Recent Company News
- 2026-04-17 12:00 EST — [Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-inc-announces-intention-to-voluntarily-file-form-25-for-delisting-from-nasdaq-and-subsequent-deregistration-with-the-sec) — Source: Lyra Therapeutics
- 2026-01-12 12:00 EST — [Lyra Therapeutics Provides Corporate Update](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-provides-corporate-update) — Source: Lyra Therapeutics
- 2025-11-12 21:01 EST — [Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update) — Source: Lyra Therapeutics
- 2025-10-06 11:00 EST — [Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-announces-clinical-plan-for-lyr-210-and-late-breaking-oral-presentation-of-phase-3-enlighten-2-study) — Source: Lyra Therapeutics
- 2025-08-12 20:01 EST — [Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update) — Source: Lyra Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)